NICE expands access for SMA drug Spinraza
Managed access agreement treatment eligibility criteria extended following review
Read More
Tag: spinal muscular atrophy
Roche’s SMA treatment Evrysdi demonstrates continued improvements in infants
Drug continuously improved motor function and survival in babies after 24 months of treatment
Read More
Roche scores EU approval for at-home SMA treatment Evrysdi
Therapy indicated for use in SMA patients aged two months and older
Read More
Zolgensma wins FDA green light in child SMA
The $2.1 milllion per treatment price tag has garnered substantial criticism.
Read More
New data reinforce effectiveness of Novartis’ Zolgensma for SMA
The Phase III STR1VE data showed that 21 patients were alive and event-free as of September 27 last year.
Read More
EU clears Biogen’s Spinraza for rare spinal disorder
EU regulators have issued clearance for the first therapy to treat spinal muscular atrophy (SMA), a rare and often fatal genetic disease affecting muscle strength and movement.
Read More
US licenses first drug for rare spinal disorder
US regulators recently approved the first therapy to treat spinal muscular atrophy (SMA), a rare and often fatal genetic disease affecting muscle strength and movement.
Read More
- Sun Pharma’s Unloxcyt now available in US for advanced cutaneous squamous cell carcinoma
- Venner Shipley announces opening of new Bristol office
- AAX Biotech and Vascurie announce new neuro-oncology collaboration
- Nxera Pharma reports positive results from phase 3 insomnia trial in South Korea
- Scottish Medicines Consortium becomes first in UK to adopt new precision gastric cancer treatment
